ARA-290

Also known as: Cibinetide, ARA 290, Erythropoietin Mimetic Peptide

Immune Modulation

Phase II

ARA-290 is an engineered peptide derived from erythropoietin that selectively activates the tissue-protective receptor complex without stimulating red blood cell production. It is primarily researched for neuropathic pain relief, nerve repair, inflammation reduction, and metabolic support in conditions like sarcoidosis and type 2 diabetes.

Regulatory & Approval Status

Not FDA Approved

ARA-290 (cibinetide) has reached phase 2 clinical trials but does not currently hold FDA approval for any medical use.

Information compiled from FDA compounding guidance and public regulatory sources. For research and educational purposes only; not medical advice.

Unlock the complete research profile

Create your free CertifiedTide account to access full compound details, mechanisms, safety data, and research tools.